Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06085937 · ClinicalTrials.gov registry record · Phase 1
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
A Phase 1 study of Depression and Suicide, sponsored by Lindsay Maguire, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT06085937: Recruiting Phase 1 study of Depression and Suicide, sponsored by Lindsay Maguire, MD.
NCT06085937 is a Phase 1 study of Depression and Suicide that is actively recruiting participants, run by Lindsay Maguire, MD. The registered enrollment target is 50 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06085937, a Phase 1 study of Depression and Suicide, is actively recruiting participants, sponsored by Lindsay Maguire, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.
Primary Outcome
Safety of use of ketamine for SI in the ED, as assessed by number and severity of reported serious adverse outcomes.
Conditions Studied
Interventions
- DRUG Ketamine
Study Locations (2)
Kansas
- University of Kansas Strawberry Hill Campus - Kansas City
- University of Kansas Medical Center Emergency Department - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
What NCT06085937 shows while recruiting
NCT06085937 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Ketamine is the first listed.
NCT06085937 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT06085937 about?
NCT06085937 is a clinical study titled "Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department". There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who pr...
What is the current status of trial NCT06085937?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-05-01. Estimated completion is 2026-04.
What conditions does trial NCT06085937 study?
This clinical trial studies the following conditions: Depression, Suicide, Suicidal Ideation.
What interventions are being tested in trial NCT06085937?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT06085937?
This trial is sponsored by Lindsay Maguire, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06085937 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06085937's enrollment target sits among peer trials
50 468th of 679 higher than 199 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
RECRUITING · Phase 1
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
RECRUITING · Phase 1
-
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy